- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Wood: Even Treatment Failures Move the Food Allergy Field Forward
Even when there are treatment failures, the knowledge gained through food allergy studies helps to move the field forward, explained Robert A. Wood, MD, director, Pediatric Allergy and Immunology, Johns Hopkins Medicine; 2018-2019 president, American Academy of Allergy, Asthma, and Immunology (AAAAI).
Even when there are treatment failures, the knowledge gained through food allergy studies helps to move the field forward, explained Robert A. Wood, MD, director, Pediatric Allergy and Immunology, Johns Hopkins Medicine; 2018-2019 president, American Academy of Allergy, Asthma, and Immunology (AAAAI).
Transcript
What lessons have you learned from the patients and their families in your food allergy studies, even from those that don’t respond to the therapy?
The lessons really are the data that comes from the study for the most part. The families that join studies tend to be highly committed to the entire experience. The kids are remarkably resilient and put up with reactions and food challenges and all those sorts of things.
The knowledge gained is what moves the field forward, and it ranges from tremendous success, where someone is virtually, completely desensitized—not cured, but they can eat food as they wish—to the 15% or so of patients who are complete treatment failures.
And then, long-term the results are, to me, a little bit discouraging. And we’re presenting here at this meeting [2019 AAAAI Annual Meeting], a long-term follow-up of our peanut studies, and over half of all the patients who we thought were successfully treated had electively gone back to strictly avoiding peanuts because they thought life was easier avoiding peanuts than taking a daily dose of peanut.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More
